Anna Casu1, Anika Bilal1, Richard E Pratley1,2. 1. AdventHealth, Translational Research Institute. 2. AdventHealth Diabetes Institute, Orlando, Florida, USA.
Abstract
PURPOSE OF REVIEW: Obesity is increasing in prevalence among patients with type 1 diabetes (T1D) and is associated with insulin resistance and increased cardiovascular risk. The management of obesity in this population is complicated by defects in pancreatic islet hormone secretion and the effects of exogenous insulin treatment. Here, we review the effects of antiobesity medications and adjunct-to-insulin medications on body weight in T1D. RECENT FINDINGS: There is a profound evidence gap around the use of drugs for the treatment of obesity in T1D since systematic studies have not been performed in this population. Adjunctive-to-insulin therapy with certain antihyperglycemic agents leads to modest weight loss and reductions in insulin dose in T1D. However, only pramlintide has been approved in the United States for clinical use as adjunctive therapy in T1D. SUMMARY: The growing prevalence of obesity in T1D has created an unmet need for safe and effective therapies to treat overweight and obesity in this population. Currently, antiobesity medications are used off-label for the treatment of patients with T1D. Additional studies are needed to understand the role of these medications in the management of obesity in patients with T1D.
PURPOSE OF REVIEW: Obesity is increasing in prevalence among patients with type 1 diabetes (T1D) and is associated with insulin resistance and increased cardiovascular risk. The management of obesity in this population is complicated by defects in pancreatic islet hormone secretion and the effects of exogenous insulin treatment. Here, we review the effects of antiobesity medications and adjunct-to-insulin medications on body weight in T1D. RECENT FINDINGS: There is a profound evidence gap around the use of drugs for the treatment of obesity in T1D since systematic studies have not been performed in this population. Adjunctive-to-insulin therapy with certain antihyperglycemic agents leads to modest weight loss and reductions in insulin dose in T1D. However, only pramlintide has been approved in the United States for clinical use as adjunctive therapy in T1D. SUMMARY: The growing prevalence of obesity in T1D has created an unmet need for safe and effective therapies to treat overweight and obesity in this population. Currently, antiobesity medications are used off-label for the treatment of patients with T1D. Additional studies are needed to understand the role of these medications in the management of obesity in patients with T1D.
Authors: Sebastian Ciężki; Emilia Kurpiewska; Artur Bossowski; Barbara Głowińska-Olszewska Journal: Front Endocrinol (Lausanne) Date: 2022-06-16 Impact factor: 6.055
Authors: Anna R Kahkoska; Angelica Cristello Sarteau; Daria Igudesman; Beth A Reboussin; Dana Dabelea; Lawrence M Dolan; Elizabeth Jensen; R Paul Wadwa; Catherine Pihoker; Elizabeth J Mayer-Davis Journal: J Diabetes Res Date: 2022-01-28 Impact factor: 4.011